Fuzhou Rides on the Opportunity of “Digital China” to Make Its Name in the World
FUZHOU, China, July 25, 2022 /PRNewswire/ -- "Discover Fuzhou: The Digital China Summit", the themed promo film of Fuzhou City, Fujian Province, was shown on "China screen" at Times Square, New York on July 22. Riding on the opportunity of "Digital China", Fuzhou, a coastal city, is presenting its "sci and tech atmosphere" at the "crossroad of the world"....
Rona Therapeutics Announces Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform
Rona to advance worldwide development of Sanofi siRNA portfolio targeting liver and other tissues Rona licensed Sanofi's siRNA platform to enable discovery programs in expanded therapeutic areas including neuro and muscular diseases, for which Sanofi has an exclusive option to acquire neuro and muscular disease candidates for ex-China territories. SHANGHAI, July 25, 2022 /PRNewswire/ -- Rona Therapeutics,...
Qiming’s Portfolio Company InventisBio Lists on STAR Market
SHANGHAI, July 25, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price is CNY 18.12 per share, representing a market cap of CNY 10.419 billion. Qiming Venture Partners invested in...
Biotech Company RemeGen Commemorates International Self-Care Day with Health Initiatives
YANTAI, China, July 25, 2022 /PRNewswire/ -- The 24th of July marks International Self Care Day, highlighting self-care as an essential component of wellness. On this special day, RemeGen Co., Ltd. (9995.HK, SHA: 688331), a commercial-stage biotechnology company, advocates an active and healthy lifestyle as a means of maintaining a high quality of life. RemeGen actively develops new drugs along...
Handheld Technology from Baxter Makes Diabetic Retinopathy Screening Simple and Affordable for Primary Care Settings
Early Detection Can Prevent 95% of Vision Loss Cases SEOUL, South Korea, July 25, 2022 /PRNewswire/ -- Diabetic retinopathy is the leading cause of blindness among working-age adults globally.1 With early detection and treatment, as much as 95 percent of vision loss cases can be prevented.2 Compliance with annual diabetic retinal exams...
US FDA APPROVES QBIOTICS INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE TIGILANOL TIGLATE SOFT TISSUE SARCOMA PHASE II TRIAL
Investigational new drug (IND) approval received by QBiotics, to initiate a Phase II clinical trial investigating tigilanol tiglate in the treatment of patients with Soft Tissue Sarcoma (STS) The open label trial will evaluate efficacy and dose ranging in patients with advanced or metastatic STS Global Data estimates that there were 124,573 new cases of STS globally in...
4DMedical Lauds U.S. House of Representatives for Including Burn Pit Population Surveillance in FY 2023 Appropriations
Thousands of Impacted Veterans Will Benefit from Congressional Efforts LOS ANGELES, July 23, 2022 /PRNewswire/ -- 4DMedical, the leading developer of functional imaging software for respiratory illness, today praised the U.S. House of Representatives for including language calling on the Department of Veterans Affairs to evaluate "emerging technology using existing x-ray imaging equipment to derive four-dimensional models of lung function"...
Vaccines alone aren’t enough to combat AMR, claims new WHO report
The Global Hygiene Council (GHC) calls for the use of hygiene practices, such as handwashing, alongside vaccinations to prevent the spread of infectious diseases and reduce the impact of antimicrobial resistance (AMR). LONDON, July 23, 2022 /PRNewswire/ -- A recent report published by the World Health Organization (WHO) identified vaccines as "highly effective tools in combating AMR". Despite their...
Nisun International Cooperates with Pinhutang Distillery to Facilitate Agricultural Product Purchases
SHANGHAI, July 22, 2022 /PRNewswire/ -- Nisun International Enterprise Development Group Co., Ltd ("Nisun" or the "Company") (Nasdaq: NISN), a provider of innovative comprehensive solutions through an integration of technology, industry, and finance, announced Fanlunke Supply Chain Management (Shanghai) Co., Ltd. ("Fanlunke"), a subsidiary of Fintech (Shanghai) Digital Technology Co., Ltd. and a controlled affiliate of the Company, has...
Alterity Therapeutics: Appendix 4C – Q4 FY22 Quarterly Cash Flow Report
Phase 2 clinical trial for ATH434 commences in New Zealand and patient enrolment begins Regulatory approval from the U.K. and Italian regulatory agencies to proceed with the Phase 2 trial A$4.1 million R&D Tax Incentive Scheme refund Cash balance on 30 June 2022 of A$34.8M MELBOURNE, Australia and SAN FRANCISCO,...
